%0 Journal Article
%@ 2369-1999
%I JMIR Publications
%V 11
%N 
%P e64611
%T Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials
%A Byrom,Bill
%A Everhart,Anthony
%A Cordero,Paul
%A Garratt,Chris
%A Meyer,Tim
%K clinical trials
%K early phase
%K dose finding
%K patient-reported outcome
%K PRO
%K electronic patient-reported outcome
%K ePRO
%K PRO-CTCAE
%K adverse events
%K tolerability
%K optimal dose
%K cancer trials
%K dose toxicity
%K oncology
%K drug development
%K electronic collection
%K dose level
%K pharmacodynamic
%K cytotoxic chemotherapy drugs
%K cytotoxic
%K chemotherapy drug
%K life-threatening disease
%K Common Terminology Criteria for Adverse Events
%D 2025
%7 28.2.2025
%9 
%J JMIR Cancer
%G English
%X While patient-reported outcome measures are regularly incorporated into phase 3 clinical trials, they have been infrequently used in early phase trials. However, the patient’s perspective is vital to fully understanding dose toxicity and selecting an optimal dose. This viewpoint paper reviews the rationale for and practical approach to collecting patient-reported outcome data in early phase oncology drug development and the rationale for electronic collection.
%R 10.2196/64611
%U https://cancer.jmir.org/2025/1/e64611
%U https://doi.org/10.2196/64611